Pediatric InvestigationPub Date : 2022-11-22eCollection Date: 2022-12-01DOI: 10.1002/ped4.12355
Jie Liu, Yuqin Huang, Suyuan Qin, Danyan Su, Bingbing Ye, Yusheng Pang
{"title":"Extracardiovascular injury complications in Kawasaki disease.","authors":"Jie Liu, Yuqin Huang, Suyuan Qin, Danyan Su, Bingbing Ye, Yusheng Pang","doi":"10.1002/ped4.12355","DOIUrl":"10.1002/ped4.12355","url":null,"abstract":"<p><strong>Importance: </strong>Patients with Kawasaki disease (KD) experience various extracardiovascular injury complications, which may affect their outcomes.</p><p><strong>Objective: </strong>To investigate the incidence and clinical characteristics of extracardiovascular complications in children with KD.</p><p><strong>Methods: </strong>The clinical data of patients diagnosed with KD in the First Affiliated Hospital of Guangxi Medical University from January 2003 to January 2021 were reviewed. The clinical characteristics and extracardiovascular complications were compared among patients stratified by age, intravenous immunoglobulin (IVIG) therapy responsiveness, and coronary status.</p><p><strong>Results: </strong>A total of 511 patients with KD were included, 357 (69.9%) were aged 1-5 years. Children aged <1 year (21.5%) and boys (70.8%) were more likely to have coronary artery lesions (CALs). The incidence of incomplete KD was lowest in 1-5-year-old patients (19.6%). Involvement of the hematological system gradually decreased with age (<1 year, 51.8%; 1-5 years, 36.7%; >5 years, 29.5%), whereas the involvement of the joints gradually increased with age (<1 year, 2.7%; 1-5 years, 6.2%; >5 years, 20.5%). Nervous system involvement was more common in IVIG non-responders (15.7% [13/83] <i>vs</i>. 5.4% [23/428], <i>P</i> = 0.001). However, there were no significant differences in extracardiovascular injury complications between patients with or without CALs.</p><p><strong>Interpretation: </strong>KD can involve multiple organ injuries as well as cardiovascular complications, and nervous systerm involvement may be more common in patients unresponsive to IVIG.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"241-249"},"PeriodicalIF":1.9,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/be/PED4-6-241.PMC9789935.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-11-15eCollection Date: 2022-12-01DOI: 10.1002/ped4.12350
Yanhui Luo, Ang Wei, Bin Wang, Guanghua Zhu, Rui Zhang, Chenguang Jia, Yan Yan, Xuan Zhou, Jun Yang, Maoquan Qin, Tianyou Wang
{"title":"Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein-Barr virus infection.","authors":"Yanhui Luo, Ang Wei, Bin Wang, Guanghua Zhu, Rui Zhang, Chenguang Jia, Yan Yan, Xuan Zhou, Jun Yang, Maoquan Qin, Tianyou Wang","doi":"10.1002/ped4.12350","DOIUrl":"10.1002/ped4.12350","url":null,"abstract":"<p><strong>Importance: </strong>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only effective treatment for chronic active Epstein-Barr virus infection (CAEBV). The clinical efficacy and safety of allo-HSCT with different conditioning regimens in children with CAEBV remain unclear.</p><p><strong>Objective: </strong>To evaluate the effectiveness and safety of allo-HSCT with the modified myeloablative conditioning (MAC) regimen for children with CAEBV and also the factors affecting the outcomes.</p><p><strong>Methods: </strong>We retrospectively analyzed children with CAEBV who underwent allo-HSCT with the modified MAC regimen at Beijing Children's Hospital, Capital Medical University from October 2016 to June 2021. Data related to the clinical manifestations, engraftment, and outcome were extracted from the medical records.</p><p><strong>Results: </strong>The cohort comprised 41 patients (24 males, 17 females) with a median transplantation age of 92.6 (60.4, 120.7) months and a median follow-up time of 28.2 (15.3, 40.2) months. Four patients (9.8%) died, among which three died from primary disease relapse, and one died from grade IV acute graft-versus-host diseases (aGVHD) after stopping treatment. The 3-year overall survival (OS) and 3-year event-free survival (EFS) rates were 88.8% ± 5.4% and 85.0% ± 5.7%, respectively. The 3-year OS and EFS did not significantly differ between the patients with hemophagocytic lymphohistiocytosis (HLH) and the patient without HLH (87.7% ± 6.8% <i>vs</i>. 91.7% ± 8.0%, <i>P</i> = 0.790; 85.0% ± 6.9% <i>vs</i>. 84.6% ± 10.0%, <i>P</i> = 0.921), or among the patients with complete remission, partial remission, and activity disease before HSCT (all <i>P</i> > 0.05). Multivariate analysis showed that grade III-IV aGVHD was a risk factor for mortality (Hazards ratio: 11.65, 95% confidence interval: 1.00, 136.06; <i>P</i> = 0.050).</p><p><strong>Interpretation: </strong>Allo-HSCT with the modified MAC regimen is safe and effective for pediatric CAEBV. This treatment benefits patients with HLH or active disease. Patients with Grade III-IV aGVHD may be associated with worse outcomes.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"250-259"},"PeriodicalIF":1.9,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/8d/PED4-6-250.PMC9789936.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10821628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is it worth already in the first step exceeding the 3-g protein limit for the oral food challenge for food protein-induced enterocolitis syndrome?","authors":"Francesco Mastellone, Giulia Bersani, Dario Sinatti, Mariannita Gelsomino, Stefano Miceli Sopo","doi":"10.1002/ped4.12351","DOIUrl":"10.1002/ped4.12351","url":null,"abstract":"","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"7 1","pages":"54-56"},"PeriodicalIF":1.9,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/d7/PED4-7-54.PMC10030697.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9193158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-11-05eCollection Date: 2022-12-01DOI: 10.1002/ped4.12352
Yumeng Gao, Hongfang Jin, Junbao Du
{"title":"Sitting intolerance: A new disease entity in children and adolescents.","authors":"Yumeng Gao, Hongfang Jin, Junbao Du","doi":"10.1002/ped4.12352","DOIUrl":"10.1002/ped4.12352","url":null,"abstract":"","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"299-301"},"PeriodicalIF":1.9,"publicationDate":"2022-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/bd/PED4-6-299.PMC9789932.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10821626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-10-24eCollection Date: 2022-12-01DOI: 10.1002/ped4.12343
Si Ding, Lianshu Han
{"title":"Newborn screening for genetic disorders: Current status and prospects for the future.","authors":"Si Ding, Lianshu Han","doi":"10.1002/ped4.12343","DOIUrl":"10.1002/ped4.12343","url":null,"abstract":"<p><p>Newborn screening (NBS) is a public health service aimed at identifying infants with severe genetic disorders, thus providing effective treatment early enough to prevent or ameliorate the onset of symptoms. Current NBS uses biochemical analysis of dried blood spots, predominately with time-resolved fluorescence immunoassay and tandem mass spectrometry, which produces some false positives and false negatives. The application of enzymatic activity-based testing technology provides a reliable screening method for some disorders. Genetic testing is now commonly used for secondary or confirmatory testing after a positive result in some NBS programs. Recently, next-generation sequencing (NGS) has emerged as a robust tool that enables large panels of genes to be scanned together rapidly. Rapid advances in NGS emphasize the potential for genomic sequencing to improve NBS programs. However, some challenges still remain and require solution before this is applied for population screening.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"291-298"},"PeriodicalIF":1.9,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/58/PED4-6-291.PMC9789938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-10-23eCollection Date: 2022-12-01DOI: 10.1002/ped4.12348
Mohammed Hamzah, Hasan F Othman, Krystel Chedid, Mohammed Alsabri, Ibrahim Qattea, Hany Aly
{"title":"Outcomes of complete surgical repair versus palliative intervention in neonates with Tetralogy of Fallot.","authors":"Mohammed Hamzah, Hasan F Othman, Krystel Chedid, Mohammed Alsabri, Ibrahim Qattea, Hany Aly","doi":"10.1002/ped4.12348","DOIUrl":"10.1002/ped4.12348","url":null,"abstract":"<p><p>Using the US National Inpatient Sample dataset (2010 to 2018), we compared outcomes of neonates with Tetralogy of Fallot who had early primary surgical repair (1726 neonate) and those who had staged palliative intervention with transcatheter (1702 neonate) or surgical palliative shunt (2661 neonate).</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"260-263"},"PeriodicalIF":1.9,"publicationDate":"2022-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/ff/PED4-6-260.PMC9789930.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10821623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-08-24eCollection Date: 2022-09-01DOI: 10.1002/ped4.12344
Michelle Fernandes, Lucinda Winckworth, Lyrille Lee, Madiha Akram, Simon Struthers
{"title":"Screening for early-onset neonatal sepsis on the Kaiser Permanente sepsis risk calculator could reduce neonatal antibiotic usage by two-thirds.","authors":"Michelle Fernandes, Lucinda Winckworth, Lyrille Lee, Madiha Akram, Simon Struthers","doi":"10.1002/ped4.12344","DOIUrl":"10.1002/ped4.12344","url":null,"abstract":"<p><strong>Importance: </strong>Effective screening strategies for early-onset neonatal sepsis (EONS) have the potential to reduce high volume parenteral antibiotics (PAb) usage in neonates.</p><p><strong>Objective: </strong>To compare management decisions for EONS, between CG149 National Institute for Health and Care Excellence (NICE) guidelines and those projected through the virtual application of the Kaiser Permanente sepsis risk calculator (SRC) in a level 2 neonatal unit at a district general hospital (DGH).</p><p><strong>Methods: </strong>Hospital records were reviewed for maternal and neonatal risk factors for EONS, neonatal clinical examination findings, and microbial culture results for all neonates born at ≥34 weeks' gestation between February and July 2019, who were (1) managed according to CG149-NICE guidelines or (2) received PAb within 72 h following birth at a DGH in Winchester, UK. SRC projections were obtained using its virtual risk estimator.</p><p><strong>Results: </strong>Sixty infants received PAb within the first 72 h of birth during the study period. Of these, 19 (31.7%) met SRC criteria for antibiotics; 20 (33.3%) met the criteria for enhanced observations and none had culture-proven sepsis. Based on SRC projections, neonates with '≥1 NICE clinical indicator and ≥1 risk factor' were most likely to have a sepsis risk score (SRS) >3. Birth below 37 weeks' gestation (risk ratio [RR] = 2.31, 95% confidence interval [CI]: 1.02-5.22) and prolonged rupture of membranes (RR = 3.14, 95% CI: 1.16-8.48) increased the risk of an SRS >3.</p><p><strong>Interpretation: </strong>Screening for EONS on the SRC could potentially reduce PAb usage by 68% in term and near-term neonates in level 2 neonatal units.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 3","pages":"171-178"},"PeriodicalIF":1.9,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/09/PED4-6-171.PMC9523803.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10721952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pediatric InvestigationPub Date : 2022-08-01eCollection Date: 2022-12-01DOI: 10.1002/ped4.12341
Yuchen Wang, Tao Li
{"title":"Advances in understanding Kawasaki disease-related immuno-inflammatory response and vascular endothelial dysfunction.","authors":"Yuchen Wang, Tao Li","doi":"10.1002/ped4.12341","DOIUrl":"10.1002/ped4.12341","url":null,"abstract":"<p><p>Kawasaki disease (KD) is a systemic vasculitis of unknown etiology, which tends to involve coronary arteries and can lead to acquired heart disease in children. The immuno-inflammatory response and vascular endothelial dysfunction are important causes of coronary artery disease in patients with KD. Multisystem inflammatory syndrome in children (MIS-C) is a rare inflammatory disease in children identified in recent years, which is caused by severe acute respiratory syndrome coronavirus 2 infection; this disease overlaps with KD. This review examines research progress concerning the immuno-inflammatory response and vascular endothelial dysfunction associated with KD, as well as differences between KD and MIS-C.</p>","PeriodicalId":19992,"journal":{"name":"Pediatric Investigation","volume":"6 4","pages":"271-279"},"PeriodicalIF":1.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/a9/PED4-6-271.PMC9789937.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10821625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}